Chardan Capital analyst Keay Nakae reiterated a Buy rating on Alnylam Pharma (ALNY) yesterday and set a price target of $150. The company’s shares closed yesterday at $90.17.
According to TipRanks.com, Nakae is ranked 0 out of 5 stars with an average return of -9.2% and a 39.8% success rate. Nakae covers the Healthcare sector, focusing on stocks such as Arbutus Biopharma Corporation, Arcturus Therapeutics Ltd, and Emergent Biosolutions.
Alnylam Pharma has an analyst consensus of Strong Buy, with a price target consensus of $128.70, implying a 42.7% upside from current levels. In a report issued on March 27, Cantor Fitzgerald also reiterated a Buy rating on the stock with a $135 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $124.22 and a one-year low of $60.27. Currently, Alnylam Pharma has an average volume of 794.9K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Alnylam Pharmaceuticals, Inc. operates as biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. It is the translation of RNAi as a new class of innovative medicines with a core focus on RNAi therapeutics for the treatment of genetically defined diseases.
